Dual actions of the Galpha(q) agonist Pasteurella multocida toxin to promote cardiomyocyte hypertrophy and enhance apoptosis susceptibility.
Dual actions of the Galpha(q) agonist Pasteurella multocida toxin to promote cardiomyocyte hypertrophy and enhance apoptosis susceptibility.
复制标题
Galpha(q) 激动剂多杀性巴斯德氏菌毒素具有促进心肌细胞肥大和增强细胞凋亡易感性的双重作用。
DOI:
10.1161/01.res.0000016165.23795.1f
复制
发表时间:
2002
影响因子:
20.1
通讯作者:
Steinberg,SusanF
中科院分区:
文献类型:
--
作者:
Sabri,Abdelkarim;Wilson,BrendaA;Steinberg,SusanF
Previous attempts to delineate the consequences of Gαqactivation in cardiomyocytes relied largely on molecular strategies in cultures or transgenic mice. Modest levels of wild-type Gαqoverexpression induce stable cardiac hypertrophy, whereas intense Gαqstimulation induces cardiomyocyte apoptosis. The precise mechanism(s) whereby traditional targets of Gαqsubunits that induce hypertrophy also trigger cardiomyocyte apoptosis is not obvious and is explored with recombinantPasteurella multocidatoxin (rPMT, a Gαqagonist). Cells cultured with rPMT display cardiomyocyte enlargement, sarcomeric organization, and increased atrial natriuretic factor expression in association with activation of phospholipase C, novel protein kinase C (PKC) isoforms, extracellular signal-regulated protein kinase (ERK), and (to a lesser extent) JNK/p38-MAPK. rPMT stimulates the ERK cascade via epidermal growth factor (EGF) receptor transactivation in cardiac fibroblasts, but EGF receptor transactivation plays no role in ERK activation in cardiomyocytes. Surprisingly, rPMT (or novel PKC isoform activation by PMA) decreases basal Akt phosphorylation; rPMT prevents Akt phosphorylation by EGF or IGF-1 and functionally augments cardiomyocyte apoptosis in response to H2O2. These results identify a Gαq-PKC pathway that represses basal Akt phosphorylation and impairs Akt stimulation by survival factors. Because inhibition of Akt enhances cardiomyocyte susceptibility to apoptosis, this pathway is predicted to contribute to the transition from hypertrophy to cardiac decompensation and could be targeted for therapy in heart failure.